학술논문
A noncanonical AR addiction drives enzalutamide resistance in prostate cancer
Document Type
article
Author
Source
Nature Communications, Vol 12, Iss 1, Pp 1-14 (2021)
Subject
Language
English
ISSN
2041-1723
Abstract
Resistance to second generation anti-androgen therapies such as enzalutamide (ENZ) can emerge in prostate cancer patients. Here, the authors identify an ENZ-resistant mechanism driven by AR-dependent transcription of noncanonical targets that make resistant cells susceptible to dual inhibition of BET and CBP/p300 signaling.